Drug Makers Say Japan's PMDA Drug Review Performance Improving
This article was originally published in PharmAsia News
Executive Summary
Japan's drug review body, the Pharmaceutical and Medical Device Agency, has significantly improved performance of the drug review process, demonstrated by shortened review times and higher satisfaction ratings, said the Office of Pharmaceutical Industry Research, a policy think tank under the industry trade association Japan Pharmaceutical Manufacturers Association